Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.

Next Previous
Trial Profile

A Phase I Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2018

At a glance

  • Drugs HQP 1351 (Primary)
  • Indications Gastrointestinal stromal tumours; Solid tumours
  • Focus Adverse reactions
  • Sponsors Ascentage Pharma

    • Most Recent Events

    • 09 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 26 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top